Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06516029
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-07
Brief Title:
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib ABL-2022-02
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A retrospective non-interventional cohort study design using data obtained from the Flatiron Health oncology electronic health record EHR-derived de-identified database was used to address the study objectives
The overall asciminib cohort included adult patients with Philadelphia positive Ph chronic myeloid leukemia CML in chronic phase CML-CP with or without the T3151 mutation who initiated asciminib in any line of therapy The third-line or later 3L asciminib cohort included adult patients with Ph CML-CP who did not have T315I mutation and initiated asciminib after prior use of at least 2 different tyrosine kinase inhibitors TKIs or omacetaxine The 3L asciminib cohort included the subgroup of the 3L asciminib cohort who initiated asciminib after prior use of 2 different TKIs or omacetaxine The fourth-line or later 4L asciminib cohort included the subgroup of the 3L asciminib cohort who initiated asciminib after prior use of at least 3 different TKIs or omacetaxine
The overall asciminib cohort included adult patients with Philadelphia positive Ph chronic myeloid leukemia CML in chronic phase CML-CP with or without the T3151 mutation who initiated asciminib in any line of therapy The third-line or later 3L asciminib cohort included adult patients with Ph CML-CP who did not have T315I mutation and initiated asciminib after prior use of at least 2 different tyrosine kinase inhibitors TKIs or omacetaxine The 3L asciminib cohort included the subgroup of the 3L asciminib cohort who initiated asciminib after prior use of 2 different TKIs or omacetaxine The fourth-line or later 4L asciminib cohort included the subgroup of the 3L asciminib cohort who initiated asciminib after prior use of at least 3 different TKIs or omacetaxine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: